Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Detection of Tick-Borne Bacteria from Whole Blood Using 16S Ribosomal RNA Gene PCR Followed by Next-Generation Sequencing
Rodino, Kyle G. , Sheldon, Sarah W., Kingry, Luke C. , Petersen, Jeannine M., Patel, Robin , Pritt, Bobbi S. , Wolf, Matthew J, Kingry, Luke , Patel, Robin , Pritt, Bobbi S , Wolf, Matthew J.

Mayo Clinic

Journal of Clinical Microbiology | February 22, 2021 | Volume: 59 | Issue: 5 | Pages: No page available

10.1128/jcm.03129-20 | PMID 33627320 Get It

Reported cases of tick-borne diseases have steadily increased for more than a decade. In the United States, a majority of tick-borne infections are caused by bacteria.
Are All Endoscopy-Related Musculoskeletal Injuries Created Equal? Results of a National Gender-Based Survey
Pawa, Swati , Banerjee, Promila, Kothari, Shivangi , D’Souza, Sharlene L., Martindale, Sarah L. , Gaidos, Jill , Burke, Carol A. , Oxentenko, Amy S. , Burke, Carol A

Mayo Clinic

American Journal of Gastroenterology | February 21, 2021 | Volume: 116 | Issue: 3 | Pages: 530-538

10.14309/ajg.0000000000001136 | PMID 33560650 Get It

INTRODUCTION: Endoscopy-related injury (ERI) is common in gastroenterologists (GI). The study aim was to assess the prevalence of self-reported ERI, patterns of injury, and endoscopist knowledge of preventative strategies in a nationally representative sample. METHODS: A 38-item electronic survey was sent to 15,868 American College of Gastroenterology physician members. The survey was completed by 1,698 members and was included in analyses. Descriptive, univariate, and multivariate analyses were conducted to evaluate the likelihood of ERI based on workload parameters and gender. RESULTS: ERI was reported by 75% of respondents. ERI was most common in the thumb (63.3%), neck (59%), hand/finger (56.5%), lower back (52.6%), shoulder (47%), and wrist (45%). There was no significant difference in the prevalence of ERI between men and women GI. However, women GI were significantly more likely to report upper extremity ERI while men were more likely to report lower-back pain-related ERI. Significant gender differences were noted in the reported mechanisms attributed to ERI. Most respondents did not discuss ergonomic strategies in their current practice (63%). ERI was less likely to be reported in GI who took breaks during endoscopy ( P = 0.002). DISCUSSION: ERI is highly prevalent in GI physicians. Significant gender differences regarding specific sites affected by ERI and the contributing mechanisms were observed. Results strongly support institution of training in ergonomics for all GI as a strategy to prevent its impact on providers of endoscopy. JOURNAL/ajgast/04.03/00000434-202103000-00021/inline-graphic1/v/2026-07-10T100418Z/r/image-tiff
SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors
Vrana, Julie A. , Terra, Simone , Jenkins, Sarah M. , Mansfield, Aaron S. , Molina, Julian R. , Cassivi, Stephen D. , Roden, Anja C. , Terra, Simone B S P , Mansfield, Aaron S , Cassivi, Stephen D , Boland, Jennifer M. , Xie, Hao

Mayo Clinic

American Journal of Clinical Pathology | February 20, 2021 | Volume: 156 | Issue: 5 | Pages: 853-865

10.1093/ajcp/aqab038 | PMID 33978159 Get It

Abstract Objectives To evaluate SATB2 expression and prognostic implications in a large cohort of thoracic neuroendocrine tumors. Methods Surgical pathology files (1995-2017) and an institutional thymic epithelial tumor database (2010-2020) were searched for resected neuroendocrine tumors. Cases were stained with SATB2 (clone EP281). Percent SATB2-positive tumor cells and expression intensity were scored. Results In the lung, SATB2 was expressed in 5% or more of tumor cells in 29 (74.4%) of 39 small cell carcinomas and 9 (22.5%) of 40 atypical and 26 (40.6%) of 64 typical carcinoid tumors. SATB2 percent tumor cell expression and intensity were higher in small cell carcinomas than in carcinoid tumors (both P < .001, respectively). After adjusting for tumor subtype, SATB2 expression did not correlate with outcome. In the thymus, four (100%) of four atypical carcinoid tumors and one large cell neuroendocrine carcinoma but no small cell carcinoma (n = 2) expressed SATB2 in 5% or more of tumor cells. Conclusions SATB2 (clone EP281) is expressed in a large subset of pulmonary and thymic neuroendocrine tumors and therefore does not appear to be a useful marker to identify the origin of neuroendocrine tumors. Validation studies are needed, specifically including thymic neuroendocrine tumors, as the expression pattern might be different in those tumors.
Effect of intracorporeal urinary diversion on the incidence of benign ureteroenteric stricture after cystectomy
Faraj, Kassem , Navaratnam, Anojan , Abdul-Muhsin, Haidar , Eversman, Sarah, Singh, Vijay Kumar , Tyson, Mark D. , Faraj, Kassem S , Rose, Kyle M., Navaratnam, Anojan K, Abdul-Muhsin, Haidar M , Singh, Vijay , Rose, Kyle

Mayo Clinic

International Journal of Urology | February 20, 2021 | Volume: 28 | Issue: 5 | Pages: 593-597

10.1111/iju.14521 | PMID 33594730 Get It

ObjectivesTo compare ureteroenteric stricture rates after radical cystectomy in patients who undergo an intracorporeal urinary diversion versus other surgical approaches.MethodsWe retrospectively reviewed health records of all patients who underwent cystectomy with urinary diversion at Mayo Clinic Hospital (Phoenix, AZ, USA) from 1 January 2007 through 1 January 2018. Ureteroenteric stricture was identified by surveillance imaging. Patients were stratified by surgical approach: open radical cystectomy, robot‐assisted radical cystectomy with extracorporeal urinary diversion and robot‐assisted radical cystectomy‐intracorporeal urinary diversion. A Cox proportional hazards model was fitted that included independent predictors of stricture development.ResultsOf the 573 cystectomies assessed, 236 (41.2%) were carried out robotically. In the robot‐assisted radical cystectomy cohort, 39 patients (16.5%) underwent intracorporeal urinary diversion. The median follow‐up period was 55, 70 and 71 months for the open radical cystectomy, robot‐assisted radical cystectomy‐extracorporeal urinary diversion and robot‐assisted radical cystectomy‐intracorporeal urinary diversion groups, respectively. Subgroup stricture rates were as follows: open radical cystectomy, 8.0%; robot‐assisted radical cystectomy‐extracorporeal urinary diversion, 9.6%; and robot‐assisted radical cystectomy‐intracorporeal urinary diversion, 2.6% (P = 0.33). The median time to stricture was 5 months (interquartile range 3.3–11.5 months). In the bivariable analysis, factors that were associated with the development of ureteroenteric stricture were postoperative urinary leak (hazard ratio 3.177, 95% confidence interval 1.129–8.935; P = 0.03) and body mass index (hazard ratio 1.078, 95% confidence interval 1.027–1.132; P = 0.002). On multivariable logistic regression analysis, intracorporeal urinary diversion approach was not associated with the development of ureteroenteric stricture (hazard ratio 0.272, 95% confidence interval 0.036–2.066; P = 0.21).ConclusionsUreteroenteric stricture is a complication that typically occurs within the first postoperative year. Although our results did not support major differences in outcomes between intracorporeal urinary diversion and extracorporeal urinary diversion, the small sample size did not exclude the possibility of a type 2 statistical error.
Establishing a SARS-CoV-2 (COVID-19) Drive-Through Collection Site: A Community-Based Participatory Research Partnership With a Federally Qualified Health Center
Woods, Cynthia , Patel, Aarti , Weis, Jennifer A., Abbenyi, Adeline, Sia, Irene G. , Berbari, Elie F. , Crane, Sarah J. , Brewer, LaPrincess C. , Weis, Jennifer, Brockman, Tabetha A. , Berbari, Elie, Crane, Sarah, Doubeni, Chyke A. , Sia, Irene G , Jones, Clarence

Mayo Clinic

American Journal of Public Health | February 18, 2021 | Volume: 111 | Issue: 4 | Pages: 658-662

10.2105/ajph.2020.306097 | PMID 33600248 Get It

The COVID-19 pandemic has disproportionately affected underserved and minority populations in the United States. This is partially attributable to limited access to diagnostic testing from deeply rooted structural inequities precipitating higher infection and mortality rates. We describe the process of establishing a drive-through collection site by leveraging an academic–community partnership between a medical institution and a federally qualified health center in Minnesota. Over 10 weeks, 2006 COVID-19 tests were provided to a socioeconomically disadvantaged population of racial/ethnic minorities and low-income essential workers.
Abstract SP094: DCIS - Con
McLaughlin, Sarah L. , McLaughlin, S

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: SP094-SP094

10.1158/1538-7445.sabcs20-sp94 Get It

Abstract Ductal carcinoma in situ (DCIS) represents a collection of biologically heterogenous pre-invasive breast lesions some with the potential for progression to invasive cancer. Widespread adoption of screening mammography has increased the diagnosis of DCIS and may contribute to overdiagnosis identifying some conditions that may never impact one’s overall health. Unfortunately, clinicians treating DCIS patients currently lack robust biomarkers stratifying DCIS patients into those at high or low risk for invasive progression. Further, variations in pathologic assessment and grade, intra-lesional DCIS heterogeneity, and discordance in pathologic interpretations between pathologists make it challenging for providers to further identify appropriate low risk DCIS patients for active surveillance. Guideline concordant care including excision and potentially radiation and anti-estrogen therapies should remain as the standard of care and provides a definitive treatment endpoint which patients desire. Existing evidence documents a significant upstage rate of DCIS to invasive disease at surgical excision including a small, but important population benefiting from adjuvant systemic therapy. Finally, patient anxiety and documented poor adherence rates to endocrine therapy preclude active surveillance and after all the morbidity of surgical excision is low. Citation Format: S McLaughlin. DCIS - Con [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr SP094.
Abstract PS6-02: Spatially defined immune-related proteins and outcome in triple negative breast cancer in the FinXX trial and Mayo Clinic cohort
Chumsri, Saranya , Ma, Yaohua , Hinerfeld, Douglas, Brauer, Heather Ann , Warren, Sarah , Perez, Edith A. , Leon‐Ferre, Roberto A. , Liu, Minetta C. , Knutson, Keith L. , Thompson, E. Aubrey , Carter, Jodi M. , Nielsen, Torsten O. , Asleh, Karama , Joensuu, Heikki , Hillman, David W. , Boughey, Judy C. , Ingle, James N. , Kalari, Krishna R. , Couch, Fergus J. , Knutson, Keith L. , Goetz, Matthew P.

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: PS6-02-PS6-02

10.1158/1538-7445.sabcs20-ps6-02 Get It

Abstract Background: Growing data established the pivotal role of preexisting immune response in triple negative breast cancer (TNBC). Conventionally, preexisting immune response can be evaluated by quantifying tumor infiltrating lymphocytes mainly in the stroma or gene expression analysis from the whole tumor section. Due to technical challenges with these conventional methods, limited data regarding specific subtypes and spatial distribution of these immune infiltrates are currently available. Methods: NanoString IO360 gene expression analysis and Digital Spatial Profiling (DSP) were used. DSP was used to quantify 29 immune-related proteins in stromal and tumor-enriched segments from 44 TNBC samples from the FinXX trial (NCT00114816) and 335 samples from the Mayo Clinic (MC) cohort of centrally reviewed TNBC (Leon-Ferre BCRT 2018). In FinXX trial, 22 patients with recurrence and 22 patients without recurrence were included. In MC cohort, 217/335 patients received adjuvant chemotherapy while 118 patients had surgery only without adjuvant chemotherapy. Regions were segmented based on pancytokeratin staining. The general linear model was used for statistical analysis of differential expression with recurrence free survival (RFS) as a categorical variable (recur yes or no). Kaplan-Meier (KM) estimates and Cox regression models were also used for analysis. Results: In the FinXX trial, there were 12 out of 29 proteins in tumor epithelial segments (intraepithelial) which were significantly expressed at higher levels among patients who were free of recurrence. These proteins include Beta-2 microglobulin, CD11c, CD20, CD40, CD56, CD8, Granzyme B, HLA-DR, ICOS, PD-L1, PD-L2, and TGFB1. In contrast, merely 5 out of 29 proteins in stromal segments were significantly differentially expressed in these 2 groups of patients. Granzyme B, IDO1, PD-L1, and PD-L2 in stroma were significantly higher and SMA was significantly lower in patients without recurrence. Using Cox regression models, intraepithelial CD56, CD40, and HLA-DR were significantly associated with outcome. When comparing between highest and lowest intraepithelial protein expression by tertile, intraepithelial CD56 (HR 0.12, 95%CI 0.03-0.39, p < 0.001), CD40 (HR 0.13, 95%CI 0.04-0.46, p = 0.002), and HLA-DR (HR 0.24, 95%CI 0.06-0.89, p = 0.032) were significantly associated with improved outcome. However, expression of these same proteins in stroma was not associated with outcome. Using KM estimates, intraepithelial CD56 (p < 0.0001), CD40 (p = 0.0006), and HLA-DR (p = 0.013) were also significantly associated with improved outcome. Nonetheless, RNA expression of these proteins by IO360 from whole tumor sections were not significantly associated with outcome (CD56 p = 0.27, CD40 p = 0.21, HLA-DR p = 0.48). Similar findings with DSP were observed in MC TNBC cohort. Comparing between the highest and lowest quartiles, there were significantly fewer patients who developed recurrence with high protein expression of intraepithelial CD56 (p < 0.001), CD40 (p = 0.002), and HLA-DR (p = 0.006). Conclusions: Using an in-depth analysis with spatially defined context, we identify that there were numerically more intraepithelial immune-related proteins associated with outcome compared to proteins in stroma. Specifically, intraepithelial CD56, CD40, and HLA-DR were significantly associated with improved outcome in both FinXX and MC TNBC cohorts. However, neither expression of these proteins in stroma nor RNA expression from whole tumor were associated with outcome. Our study highlights the impact of spatial biology and the importance of evaluating each potential biomarker in a spatially defined manner. Support: W81XWH-15-1-0292, BCRF 19-161, P50CA116201-9, P50CA015083 Citation Format: Saranya Chumsri, Jodi M. Carter, Yaohua Ma, Douglas Hinerfeld, Heather Ann Brauer, Sarah Warren, Torsten O. Nielsen, Karama Asleh, Heikki Joensuu, Edith A. Perez, Roberto A. Leon-Ferre, David W. Hillman, Judy C. Boughey, Minetta C. Liu, James N. Ingle, Krishna R. Kalari, Fergus J. Couch, Keith L. Knutson, Matthew P. Goetz, E. A. Thompson. Spatially defined immune-related proteins and outcome in triple negative breast cancer in the FinXX trial and Mayo Clinic cohort [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS6-02.
Abstract PD7-05: Neoadjuvant chemotherapy selectively alters spatially-defined immune landscapes in clinical luminal B HR+/HER2- breast cancers: Analysis of the breast cancer genome guided therapy study (BEAUTY)
He, Jun, Kachergus, Jennifer M., Wang, Liewei , Weinshilboum, Richard, Moyer, Ann M. , McLaughlin, Sarah A., Moreno‐Aspitia, Alvaro , Northfelt, Donald W. , Gray, Richard J. , Thompson, E. Aubrey , Carter, Jodi M. , Boughey, Judy C. , He, Jun, Suman, Vera J. , Wang, Xue , Kalari, Krishna R. , Ingle, James N. , Goetz, Matthew P.

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: PD7-05-PD7-05

10.1158/1538-7445.sabcs20-pd7-05 Get It

Abstract Introduction: The immune microenvironment of high-risk HR+ breast cancer (BC) is poorly understood. BEAUTY is a prospective neoadjuvant chemotherapy (NAC) study of stage I-III BC patients treated with neoadjuvant weekly taxane followed by anthracycline-based chemotherapy. Among clinical luminal B BC (St. Gallen criteria) from BEAUTY, we used high-plex digital spatial profiling (DSP) to characterize the intra-epithelial tumor and stromal immune landscapes to 1) assess the impact of NAC on these landscapes and 2) identify immune biomarkers predictive of response to NAC. Methods: The tissue set included FFPE sections of resected tumors from 35 patients (median 51y; range: 21-71y) with clinically-defined luminal B BC (ER > 10%/grade 2/Ki67 ≥ 15% or ER > 10%/grade 3), and 16 paired pre-NAC biopsies. Nanostring GeoMX DSP was used to quantitate 58 immune and BC biomarker proteins in intra-epithelial, cytokeratin-positive tumor segments and adjacent stromal (cytokeratin-negative/SYTO13 (nuclear stain)-positive) segments. Data were normalized using the geometric mean of two negative controls (RbIgG and MsIgG1). A general linear model with negative binomial identified differentially-expressed (DE) proteins in pre/post-NAC tumors. Based on DE protein data and biologic function, a targeted protein subset (N=19) was evaluated in pre-NAC biopsies for associations between protein abundance and residual cancer burden (RCB) class (0-II vs. III) (Wilcoxon-rank sum test: p-value < 0.025 considered significant) or RCB ‘breast only’ index (Spearman correlation). Results: Comparing tumor segments in pre-NAC specimens, intra-epithelial segments were predictably enriched in cytokeratin, ER, PR and Ki-67, but also CD127 and NY-ESO-1; whereas stromal segments were enriched in proteins associated with T cell subsets (e.g. CD3, CD4, CD8), macrophages (CD68 and CD163), antigen presentation/dendritic cells (CD11c, HLA-DR) and immune checkpoint proteins (PD-L1, PD-L2, B7-H3, TIM-3, VISTA) among others. While NAC did not alter the spatial distribution of proteins (intra-epithelial vs. stromal segments), it markedly attenuated the immune landscape, with decreased abundance of functionally-diverse immune proteins (e.g. CD45, CD3, CD4, CD127, granzyme B, CTLA4; STING, B7-H3, CD11c, and CD68, log2FC: 0.27-1.52 p < 0.05), including low abundance proteins PD-1, PD-L1, PD-L2, CD20, and OX40L (log 2FC: 0.15-1.16, p < 0.05). Both PR and Ki-67 decreased in post-NAC tumors whereas ER was not significantly altered (p < 0.05). CD8, CD14, CD163, HLA-DR, IDO-1 and TIM-3 were not significantly altered by NAC. In the pre-NAC biopsies (which had subsequent residual tumor burdens of RCB class 0 or I (n=1 each), II (n=6), and III (n=8), and median RCB ‘breast only’ index of 3.39 (range: 0.00-38.02), 19 proteins were used for RCB analysis (CD3, CD4, CD8, CD14, CD34, CD44, CD45, CD68, CD127, CD163, CTLA4, granzyme B, STING, B7-H3, fibronectin, Ki-67, HLA-DR, SMA and TIM3). Among them, stromal CD127 was significantly higher in RCB class III than RCB class 0-II (p=0.021) and RCB ‘breast only’ index was positively correlated with intra-epithelial granzyme B (rho = 0.61; p=0.012), and negatively correlated with intra-epithelial Ki-67 (rho= -0.71; p=0.0022). Conclusion: In this series of clinical luminal B BC, NAC markedly attenuated the tumoral immune landscapes with a small set of “NAC-resistant” immune proteins. Among a targeted set, stromal CD127 was significantly higher in RCB III, and RCB breast-only index was positively correlated with intra-epithelial granzyme B. These data provide insight into the impact of NAC on HR+ BC, and identify potential immune biomarkers to predict response to neoadjuvant chemotherapy. Citation Format: Jodi M Carter, Judy C Boughey, Jun He, Vera J Suman, Xue Wang, Jennifer M Kachergus, Krishna R Kalari, Liewei Wang, Richard Weinshilboum, Ann M Moyer, Sarah A McLaughlin, Alvaro Moreno-Aspitia, Donald W Northfelt, Richard J Gray, James N Ingle, E. Aubrey Thompson, Matthew P Goetz. Neoadjuvant chemotherapy selectively alters spatially-defined immune landscapes in clinical luminal B HR+/HER2- breast cancers: Analysis of the breast cancer genome guided therapy study (BEAUTY) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD7-05.
Abstract PD7-04: Association between patient derived xenograft (PDX) take rate and breast cancer recurrence in the prospective breast cancer genome guided therapy study (BEAUTY)
Yu, Jia , Santo, Katelyn, McLaughlin, Sarah A., Aspitia, Alvaro Moreno, Copland, John A. , Northfelt, Donald W. , Gray, Richard J. , Hunt, Katie N. , Conners, Amy Lynn , Weinshilboum, Richard, Wang, Liewei , Boughey, Judy C. , Suman, Vera J. , Sinnwell, Jason P. , Carter, Jodi M. , Kalari, Krishna R. , Tang, Xiaojia , Goetz, Matthew P.

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: PD7-04-PD7-04

10.1158/1538-7445.sabcs20-pd7-04 Get It

Abstract Background: Patient derived xenografts are a standard tool used to study cancer biology and evaluate drug response phenotypes. It is well known that PDX take rate is associated with more aggressive clinical features [higher grade, biologic subtype (e.g. TNBC vs luminal)]. Previous data from a small retrospective cohort of patients (pts) with no prior chemo (n=24) suggested that primary breast tumor PDX take rate was associated with reduced overall survival. (Derose Nat Med. 2011) However, whether take rate is prognostic in newly diagnosed pts receiving standard of care neoadjuvant chemotherapy (NAC) is unknown. From the prospective BEAUTY clinical trial of pts treated with NAC in which PDX was attempted from pre-NAC as well as after chemo (post-NAC), we recently reported no difference in take rate comparing pts with or without a pathologic complete response (pCR) (Yu Breast Canc Res 2018). Herein we report the association between PDX take rate and recurrence from tumor samples implanted pre-NAC as well as post-NAC (time of surgery). Methods: The BEAUTY study is a prospective NAC study which enrolled breast cancer pts (Stage I-III; n=140) treated with neoadjuvant weekly taxane +/-trastuzumab followed by anthracycline-based chemotherapy. Percutaneous tumor biopsies were obtained prior to NAC and tumor samples from residual disease at surgery were additionally used to establish PDXs. Tumor take rate was defined as percent of pts with the development of at least one stably transplantable (passed at least for four generations) xenograft that was pathologically confirmed as breast cancer. Time to breast cancer recurrence was defined as the time from surgery to documentation of a local, regional, or distant recurrence. Gray’s test was used to assess whether the cumulative incidence (CI) of a breast cancer recurrence differs with respect to either pre-NAC PDX take or post-NAC PDX take. Results: Of 140 pts enrolled in the BEAUTY study, tumor tissue for PDX from the pre-NAC tumor was available for implantation in 113. As previously published, PDX take rate from pre-NAC tumor was 27.4% (31/113), and varied according to tumor clinical subtype [51.3% (20/39) in triple negative breast cancer (TNBC), 26.5% (9/34) in HER2+, 5.0% (2/40) in Luminal]. With median follow up of 5.7 years (range: 3 months to 6.75 years), 17 pts developed local, regional or distant disease relapse (4 of whom had a PDX established pre-NAC). The cumulative incidence of breast cancer relapse after surgery was not found to differ according to pre-NAC PDX take (5 yr CI rate: 13.6% no take; 13.4% take; p=0.8911). In pts with TNBC, the group with the highest take rate, there was also no significant difference in incidence of BC recurrence between those without PDX take and those with PDX take (5 yr CI rate: 21.4% vs 16.2% p=0.7314). PDXs were established from residual tissue from surgery (post-NAC) in 6 of 34 pts (17.6%), [specifically, TNBC: 5/9; Her2+: 1/8; and Luminal: 0/17]. Nine of these 34 pts developed a local, regional or distant recurrence. There was a tendency for pts who had a PDX established from their residual disease to have a higher incidence of a breast event (p=0.1092). The 5 year cumulative incidence of a breast event was 19.6% for pts whose post-NAC PDX did not take and 50.0% for pts whose post-NAC PDX took. Discussion: In pts receiving NAC for breast cancer, we observed no significant difference between establishment of a pre-NAC PDX and breast cancer relapse. In contrast, post-NAC PDX take rate (from residual tumor obtained from the breast at surgery) was associated with a tendency to have a higher incidence of a breast cancer event. PDXs remain a valuable tool for the evaluation of tumor biology and development of new therapeutics, especially those models established from pts with chemotherapy resistance. Citation Format: Judy C. Boughey, Vera J. Suman, Jia Yu, Katelyn Santo, Jason P. Sinnwell, Jodi M. Carter, Krishna R. Kalari, Xiaojia Tang, Sarah A. McLaughlin, Alvaro Moreno Aspitia, John A. Copland, III, Donald W. Northfelt, Richard J. Gray, Katie N. Hunt, Amy Lynn Conners, Richard Weinshilboum, Liewei Wang, Matthew P. Goetz. Association between patient derived xenograft (PDX) take rate and breast cancer recurrence in the prospective breast cancer genome guided therapy study (BEAUTY) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD7-04.
Abstract PD14-09: Nci 10013 - A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel, with or without atezolizumab in triple negative breast cancer (TNBC)
Chen, Ina , Northfelt, Donald W. , Arora, Mili, Dees, Claire, Santa‐Maria, Cesar A. , Connolly, Roisín M. , Force, Jeremy , Moreno‐Aspitia, Alvaro , Larson, Sarah , Gillanders, William E. , Ademuyiwa, Foluso O. , Gao, Feng , Wesolowski, Robert , Brufsky, Adam , Santa-Maria, Cesar Augusto , Larson, Sarah, Sharon, Elad

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: PD14-09-PD14-09

10.1158/1538-7445.sabcs20-pd14-09 Get It

Abstract Background Inhibition of PD-L1 with atezolizumab combined with chemotherapy has shown acceptable safety and improved survival in patients with metastatic PD-L1 positive triple negative breast cancer (TNBC). Patients with TNBC who do not achieve a pathological complete response (pCR) to neoadjuvant chemotherapy have a high risk of disease recurrence and death. This randomized, open-label, phase 2 trial evaluates neoadjuvant carboplatin and paclitaxel with or without atezolizumab in patients with previously untreated clinical stages II and III TNBC. Methods Women aged ≥18 years with clinical stage T2-T4c, any N, M0 primary tumor by AJCC 7th edition staging TNBC; ECOG PS 0-2; and no prior systemic therapy for the indexed breast cancer were eligible. Patients were randomized in a 1:2 ratio to carboplatin AUC5 q 3 weeks x 4 + paclitaxel 80 mg/m2 q week x 12 (Arm A), or carboplatin AUC5 q 3 weeks x 4 + paclitaxel 80 mg/m2 q week x 12 + atezolizumab 1200 mg q3 weeks x 4 (Arm B). Surgery was 3-6 weeks following neoadjuvant chemotherapy. Adjuvant dose-dense doxorubicin and cyclophosphamide was administered q2 weeks with growth factor support to all patients as per routine care. pCR and tumor infiltrating lymphocyte (TIL) percentages are the co-primary endpoints. pCR-evaluable population includes all eligible women who have been randomized and received at least one dose of combination therapy, while the TIL-evaluable population includes all eligible women who have evaluable TIL percentage after one cycle of therapy. A sample size of 67 (22 in Arm A, and 45 in Arm B) provided 80% power at 1-sided alpha = 0.10 to detect a minimum of 15% difference in TIL and 29% improvement (40% vs. 69%) in pCR, respectively. Herein, we report pCR results in the per protocol modified intent-to-treat population (mITT), which includes all eligible patients who were randomized and received at least one dose of combination therapy. Results Sixty-seven patients were randomized between 8/2017 and 9/2019. Six patients randomized to Arm A withdrew consent; 2 of these received protocol therapy but are excluded from the mITT analyses as they are not evaluable because definitive pathology reports are not available. Median follow up is 6 months (range 0.3 - 12.6 months). Median age is 52 years (range 25 - 78). Forty-three (64.2%) were Caucasian and thirteen (19.4%) were African American. Twenty-five (37.3%) were pre-menopausal. 67.2% and 32.8% had stages II and III disease respectively. Nine (13.4%) had a germline mutation in either BRCA1 or BRCA2. In the mITT population, 3 of 16 patients achieved pCR in Arm A - 18.8% (95% CI 4.0%- 45.6%), versus 25 of 45 patients in Arm B - 55.6% (95% CI 40.0%-70.4%); p value 0.018. pCR in those with BRCA mutations was 50% and 80% in Arm A and Arm B, respectively. Treatment delays were observed in 9 patients (40.9%) in Arm A, and 20 (44.4%) in Arm B; dose reductions occurred in 4 patients (18.1%) in Arm A, and in 6 (13.3%) in Arm B. There were 4 SAEs in Arm A and 10 in Arm B. One patient in Arm B had grade 3 adrenal insufficiency. One patient in Arm B died from recurrent disease during the follow-up period. Conclusions: The addition of atezolizumab to neoadjuvant carboplatin and paclitaxel resulted in an increased pCR rate in patients with clinical stages II and III TNBC. However, the pCR in the control Arm A was lower than expected, possibly due to the absence of neoadjuvant anthracyclines. The high pCR rate observed in the experimental arm of this study is similar to that observed in other neoadjuvant trials utilizing anthracyclines, taxanes, and carboplatin in TNBC. Clinical trial information: NCT02883062. Citation Format: Foluso O Ademuyiwa, Feng Gao, Ina Chen, Donald W Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, Claire Dees, Cesar A Santa-Maria, Roisin M Connolly, Jeremy Force, Alvaro Moreno-Aspitia, Sarah Larson, Elad Sharon, William Gillanders. Nci 10013 - A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel, with or without atezolizumab in triple negative breast cancer (TNBC) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD14-09.